Epilepsy News and Research

Latest Epilepsy News and Research

USF study: HHV-6 causes permanent infection by inserting its DNA into human chromosomes

Human herpesvirus 6 (HHV-6) infects nearly 100 percent of humans in early childhood, and the infection then lasts for the rest of a person's life. Now, a team led by Peter Medveczky, MD, a professor in the Department of Molecular Medicine at the University of South Florida, has discovered that in some individuals, HHV-6 causes such a permanent infection by inserting or "integrating" its DNA into human chromosomes.

9 Mar 2010

UCB Rheumatoid Arthritis Family Scholarship applications open until March 19, 2010

Applications are being accepted until March 19, 2010 for the UCB Rheumatoid Arthritis Family Scholarship. These scholarships are for rheumatoid arthritis patients or their immediate family members. Winners are awarded up to $10,000 to continue their studies at an accredited institution of higher education in the U.S.

6 Mar 2010

Natus Medical reports increased revenue for 2009 fourth quarter

For the fourth quarter ended December 31, 2009, Natus reported revenue of $51.6 million, compared to $43.4 million reported in the comparable quarter of the previous year. Net income was $4.3 million, or $0.15 per diluted share, for the fourth quarter of 2009, compared with net income of $6.3 million, or $0.22 per diluted share, for the fourth quarter of 2008.

4 Mar 2010

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy - the most common form of epilepsy in kids - has established an evidence-based approach for initial drug therapy.

4 Mar 2010

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

Anavex Life Sciences Corp. today issued a statement following today's announcement from Pfizer and Medivation (MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.

4 Mar 2010

NAEC elects Mayo Clinic as top epilepsy treatment center

Mayo Clinic has been designated a comprehensive epilepsy treatment center by the National Association of Epilepsy Centers (NAEC). Only the top epilepsy programs - those that can provide the most complex and advanced care - are selected for this designation, according to the association.

3 Mar 2010

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.

26 Feb 2010

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

MicroTransponder, Inc., a privately-held medical device company, has just announced a $7 Million Series B round of funding. MicroTransponder is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications.

25 Feb 2010

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.

23 Feb 2010

Aeolus Pharmaceuticals' first fiscal quarter net loss rises

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months ended December 31, 2009. The Company reported a net loss of $15,276,000, or $0.33 per basic share, compared to a loss of $459,000, or $0.01 per basic share, for the three months ended December 31, 2008.

19 Feb 2010

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets.

19 Feb 2010

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Catalyst Pharmaceutical Partners, Inc. announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco.

18 Feb 2010

Anti-seizure medication prevents seizures in patients following bleeding stroke: Study

A study by researchers at the University of Cincinnati Neuroscience Institute at University Hospital supports the use of an alternative medication to prevent seizures in patients who have suffered a life-threatening traumatic brain injury or bleeding stroke.

18 Feb 2010

FDA issues Complete Response Letter for Horizant in treatment of RLS

GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).

18 Feb 2010

Cyberonics approves new share repurchase program

Cyberonics, Inc. today announced that its board of directors has approved a new share repurchase program. The company's board of directors had previously authorized a repurchase of up to 1.0 million shares, of which a total of 515,000 shares were repurchased.

18 Feb 2010

Ibuprofen may reduce risk of Parkinson's disease, says study

New research shows people who regularly take ibuprofen may reduce their risk of developing Parkinson's disease, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

18 Feb 2010

Epilepsy News and Research

Latest Epilepsy News and Research

USF study: HHV-6 causes permanent infection by inserting its DNA into human chromosomes

UCB Rheumatoid Arthritis Family Scholarship applications open until March 19, 2010

Natus Medical reports increased revenue for 2009 fourth quarter

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

NAEC elects Mayo Clinic as top epilepsy treatment center

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Aeolus Pharmaceuticals' first fiscal quarter net loss rises

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Anti-seizure medication prevents seizures in patients following bleeding stroke: Study

FDA issues Complete Response Letter for Horizant in treatment of RLS

Cyberonics approves new share repurchase program

Ibuprofen may reduce risk of Parkinson's disease, says study

Research suggests scorpion venom could be an alternative to morphine painkiller

New foundational research may advance pharmacological therapies for neurological disorders

Migraine is seen more frequently in women with MS than those without: Study

Meda publishes 2009 year-end report

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Epilepsy News and Research

Latest Epilepsy News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in